ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 4.90

Change

-0.04 (-0.81)%

Market Cap

USD 0.13B

Volume

0.06M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Armata Pharmaceuticals Inc (ARMP) Stock Analysis:
Based on the Armata Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Armata Pharmaceuticals Inc is not available over the next 12 months. Armata Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Armata Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Armata Pharmaceuticals Inc’s stock price was USD 4.90. Armata Pharmaceuticals Inc’s stock price has changed by -0.06 % over the past week, +0.95 % over the past month and +55.56 % over the last year.

About

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. Th ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+2.41 (+2.24%)

USD244.19B 35.48 3.81
DNA Ginkgo Bioworks Holdings

+0.24 (+2.46%)

USD12.86B N/A N/A
BHVN Biohaven Pharmaceutical Holdin..

+4.90 (+4.89%)

USD7.36B N/A N/A
RCUS Arcus Biosciences Inc

+1.87 (+4.27%)

USD3.11B N/A N/A
ADCT ADC Therapeutics SA

+1.27 (+6.33%)

USD1.65B -99,999.99 N/A
MYOV Myovant Sciences Ltd

+1.07 (+7.09%)

USD1.37B N/A N/A
ZYME Zymeworks Inc

+0.03 (+0.16%)

USD0.94B 300.20 N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
CVM CEL-SCI Corporation

+1.00 (+11.21%)

USD0.37B N/A N/A
LCTX Lineage Cell Therapeutics Inc

+0.18 (+8.49%)

USD0.37B 3.63 N/A

ETFs Containing ARMP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 64.43% 93% A 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.43% 93% A 91% A-
Trailing 12 Months  
Capital Gain 55.56% 93% A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.56% 93% A 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.45% 37% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.45% 37% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 21.27% 89% B+ 54% F
Risk Adjusted Return 25.62% 41% F 29% F
Market Capitalization 0.13B 47% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.60 47% F 17% F
Price / Cash Flow Ratio -7.28 67% D+ 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -98.12% 41% F 9% F
Return on Invested Capital -126.34% 38% F 1% F
Return on Assets -34.28% 34% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.18 97% A+ 91% A-
Short Percent 0.03% 100% A+ 98% A+
Beta -0.13 88% B+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector